New pill could tame rare genetic diabetes

NCT ID NCT06976658

Recruiting now Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called dorzagliatin in 44 adults with a rare, inherited form of diabetes (GCK-MODY). The drug works by activating a key enzyme to help the body better control blood sugar. Participants will receive both the drug and a placebo at different times to see if the drug improves blood sugar levels and other measures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dorzagliatin (a drug that activates glucokinase, an enzyme that helps regulate blood sugar)
What this could lead to: If successful, this could provide a targeted oral treatment option for people with GCK-MODY, potentially improving blood sugar control without the need for insulin or other diabetes drugs.
What could go wrong: This is a small, early-phase (Phase 2) trial with only 44 participants, so results may not apply to everyone. The drug may not significantly improve blood sugar or could have side effects. It is not a cure, as ongoing treatment would likely be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus maturity-onset diabetes of the young type 2 monogenic diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS MONOGENIC DIABETES

Contacts and locations

Locations

3M, Diabetes and Endocrine Research Center
RECRUITING

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.